Amgen (NASDAQ:AMGN) Stock Quotes and News

174.83 2.89 (1.68%)

After Hours 174.87 (%)

Data as of Apr 25, 2018

Prev. Close 171.94
Price Open 173.66
Volume 4,693,756
Day's Range 170.34 - 175.44
52 Wk Range 152.16 - 201.23
50 Day Moving Avg. 178.99
PE Ratio 63.918216
Shares Outstanding 730.70M
Market Cap 127.75B

Trade AMGN stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
4/25/18	Morgan Stanley	Maintains	OverweightOverweight	200.0
4/05/18	Barclays	Maintains	Equal-WeightEqual-Weight	180.0
2/05/18	Atlantic Equities	Downgrades	OverweightNeutral	0.0

Benzinga's Top Analyst Calls From April 25, 2018 Bill HaddadWed, 25 Apr 2018 14:43:24 -0400
Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises Elizabeth BalboaWed, 25 Apr 2018 12:11:44 -0400
Cowen Out Positive Following Amgen Earnings, Calling It One Of The Better Financial Reports For The Co. In Some Time; Says That The Stock Is Inexpensive And Could Benefit From Significant Multiple Expansion Eddie StaleyWed, 25 Apr 2018 09:49:14 -0400
Morgan Stanley Maintains Overweight on Amgen, Lowers Price Target to $200.00 Vick MeyerWed, 25 Apr 2018 09:03:41 -0400
Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen Shanthi RexalineWed, 25 Apr 2018 07:46:04 -0400
Amgen Says Board Increased Amount Authorized Under Co's Stock Repurchase Program by Additional $5B Charles GrossWed, 25 Apr 2018 06:19:10 -0400
Amgen Sees FY18 Adj. EPS $12.80-$13.70 vs $13.48 Est., Sales $21.9-$22.8B vs $22.6B Est. Eddie StaleyTue, 24 Apr 2018 16:02:30 -0400
Amgen Q1 EPS $3.47 Beats $3.24 Est., Sales $5.6B Beats $5.43B Est. Eddie StaleyTue, 24 Apr 2018 16:01:45 -0400
Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches Elizabeth BalboaTue, 24 Apr 2018 12:49:45 -0400
Reuters Reported That Express Scripts Is Telling Drugmakers That The Current Pricing Model Is Broken; Co. Is Taking Aim At Amgen And Other Makers Of New Migraine Medicines To Try And Fix It Eddie StaleyTue, 24 Apr 2018 06:33:10 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Amgen Reports First Quarter 2018 Financial Results PRNewswire1 day ago
Technical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio Pharma PRNewswire5 days ago
Amgen Announces Webcast Of 2018 First Quarter Financial Results PRNewswire6 days ago
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures PRNewswireApr 17, 2018
Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant PRNewswireApr 10, 2018
Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018 PRNewswireApr 09, 2018
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma PRNewswireApr 03, 2018
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children PRNewswireMar 29, 2018
Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer Business WireMar 29, 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes PRNewswireMar 23, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales Zacks5 hours ago
Amgen Inc. 2018 Q1 - Results - Earnings Call Slides Seeking Alpha7 hours ago
AbbVie files U.S. marketing application for plaque psoriasis med risankizumab Seeking Alpha13 hours ago
Facebook Steps Up To The Earnings Plate, Comcast Bids For Sky (Wall Street Breakfast Podcast) Seeking Alpha13 hours ago
Wall Street Breakfast: Facebook Back In The Spotlight Seeking Alpha15 hours ago
Amgen's (AMGN) CEO Bob Bradway on Q1 2018 Results - Earnings Call Transcript Seeking Alpha21 hours ago
Mr. Market Grasps the Esoteric GuruFocus1 day ago
Amgen Q1 revenues up 2%; earnings up 12%; cash flow up 14%; earnings guidance raised; shares up 1% after hours Seeking Alpha1 day ago
Amgen beats by $0.22, beats on revenue Seeking Alpha1 day ago
Hemenway Trust Co LLC Buys Fiserv Inc, Celgene Corp, NVIDIA Corp, Sells MarketAxess Holdings ... GuruFocus1 day ago
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q1 2018	EST	Actual	Surprise
EPS:	3.22	3.47	0.25
Rev:	5.41B	5.55B	144.00M

Q2 2018	EST	Actual	Surprise
EPS:	Expected 2018-07-24
Rev:	Expected 2018-07-24

Brokerage Center

Compare All Online Brokerages

Market Overview

Amgen Inc. AMGN:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Amgen Inc. AMGN:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners